Tradestie Institutional Equity Comparison Engine
NVS vs ABBV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABBV Overall Edge
ABBV Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abbvie Inc. (ABBV) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while NVS counters with relative strength in Valuation. Fundamentally, NVS trades at 16.2x Forward P/E with 34.0% operating margin (+4.7% YoY revenue) versus ABBV at 18.2x Forward P/E and 36.6% operating margin (+10.3% YoY). In options structure, NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against ABBV sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
NVS
NVS 16.2x vs ABBV 18.2x Fwd P/E
Growth & Margin Winner
ABBV
Op Margin 34.0% vs 36.6% ยท YoY +4.7% vs +10.3%
Momentum & Technical Winner
ABBV
1Y +22.5% vs +27.4% ยท 52W Pos 81% vs 94%
Options & Structure Winner
ABBV
UNCLASSIFIED (6th %ile IV) vs BREAKOUT (12th %ile IV)
NVS
NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap
$302.9B
1M Return
+7.28%
1Y Return
+22.5%
Forward P/E
16.2x
Unified AI Score
41.5 / 100
SELL
Tech 29.0
Fund 38.0
Flow 50.0
Mom 21.1
ABBV
NYSE
Abbvie Inc.
Pharmaceutical Preparations
$295.94
+0.31% 1D
Market Cap
$520.5B
1M Return
+3.69%
1Y Return
+27.4%
Forward P/E
18.2x
Unified AI Score
54.0 / 100
HOLD
Tech 34.0
Fund 50.0
Flow 72.0
Mom 46.1
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NVS +22.5%
ABBV +27.4%
Spread: +4.9 pp (ABBV Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NVS TTM Op. Margin: 34.0%
ABBV TTM Op. Margin: 36.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs ABBV. Trailing 12-month operating profitability (NVS 34.0% vs ABBV 36.6%) and valuation multiples (NVS 16.2x vs ABBV 18.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NVS | ABBV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $302.9B | $520.5B | Larger Scale | ABBV |
| Trailing P/E Ratio Valuation | 30.6x | 50.6x | Lower Multiple | NVS |
| Forward P/E Ratio Valuation | 16.2x | 18.2x | Lower Multiple | NVS |
| Revenue Growth (YoY) Growth | +4.7% | +10.3% | Higher Growth | ABBV |
| Operating Margin (TTM) Profitability | 34.0% | 36.6% | Higher Margin | ABBV |
| Net Profit Margin Profitability | 17.5% | 15.7% | Higher Margin | NVS |
| Return on Equity (ROE) Capital Efficiency | 24.3% | 62.3% | Higher ROE | ABBV |
| 52-Week Range Position Momentum | 81% ($123โ$170) | 94% ($191โ$303) | Stronger Trend | ABBV |
| Beta / 30D Volatility Risk Regime | 0.31ฮฒ ยท 27% Vol | -0.03ฮฒ ยท 20% Vol | Lower Realized Risk | ABBV |
| Unified Institutional Score Composite Signal | 41.5 / 100 (SELL) | 54.0 / 100 (HOLD) | Higher Composite | ABBV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NVS vs ABBV Buy Guide
NVS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
ABBV
BREAKOUT
94d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NVS nor ABBV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.